+31.6%
SWKS vs MRNA
+786.4%
-754.7%
-72.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.0% | -2.2% | -3.9% | -5.9% |
| 7D | -17.8% | -12.7% | -5.1% | -17.1% |
| 30D | -10.1% | -20.7% | +10.6% | -9.0% |
| 3M | +8.8% | +46.3% | -37.5% | +5.3% |
| 6M | +0.3% | +305.2% | -305.0% | -16.2% |
| YTD | +19.0% | +561.2% | -542.3% | -7.4% |
| 1Y | +24.7% | +772.1% | -747.4% | -6.3% |
| 3Y | -14.6% | +147.0% | -161.6% | -28.9% |
| 5Y | -47.0% | -26.1% | -21.0% | -53.4% |
| All | +31.6% | +786.4% | -754.7% | +10.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling